Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism.

CONTEXT It is unclear whether bone mineral density (BMD) improves in patients with normocalcemic primary hyperparathyroidism (PHPT) after parathyroidectomy (PTX). OBJECTIVE The objective of the study was to evaluate and compare the impact of PTX on BMD change at 1 year in normocalcemic vs hypercalcemic PHPT. DESIGN This was a longitudinal cohort study. SETTING The study took place at a referral center. PATIENTS We included 60 PHPT patients (mean age 64.0 ± 10.1 years), successfully treated by PTX by the same surgeon. Two groups were individualized according to baseline serum total (albumin corrected) calcium: 39 patients with normal baseline serum total calcium (normocalcemic group) and 21 patients with hypercalcemia at baseline (hypercalcemic group). MAIN OUTCOME MEASURE BMD changes 1 year after PTX were measured. RESULTS In the normocalcemic group, BMD increased significantly by +2.3 ± 5.0% at the spine (P = .016) and +1.9 ± 5.7% at the hip (P = .048). In the hypercalcemic group, BMD increased significantly by +4.0 ± 3.8% at the spine (P = .0003) and +3.2 ± 4.2% at the hip (P = .003). There was no difference in these BMD gains between both groups (P > .1). The presence of multiple adenomas or hyperplasia was more frequent in the normocalcemic group than in the hypercalcemic group (P = .04). CONCLUSION Our results indicate for the first time that successful PTX in normocalcemic PHPT patients with osteoporosis is followed with mild but significant BMD improvement at the spine and hip at 1 year, comparable with that observed in hypercalcemic PHPT, suggesting that PTX may be beneficial in normocalcemic PHPT.

[1]  J. Sáez Primary Hyperparathyroidism Focused on Molecular Pathogenesis. , 2014 .

[2]  M. Muñoz-Torres,et al.  Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women , 2012, Endocrine.

[3]  Tracy S. Wang,et al.  Surgical Management of Normocalcemic Primary Hyperparathyroidism , 2012, World Journal of Surgery.

[4]  S. Silverberg,et al.  Normocalcemic primary hyperparathyroidism. , 2010, Arquivos brasileiros de endocrinologia e metabologia.

[5]  J. Miller,et al.  Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Eisner,et al.  Differentiating primary from secondary hyperparathyroidism in stone patients: the "thiazide challenge". , 2009, Journal of endourology.

[7]  L. Mosekilde,et al.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  K. Albain,et al.  Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Arrieta,et al.  Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion , 2008, Journal of endocrinological investigation.

[10]  E. Siris,et al.  The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  L. Mosekilde,et al.  Primary hyperparathyroidism and the skeleton , 2008, Clinical endocrinology.

[12]  P. Vestergaard,et al.  Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism , 2008, Clinical endocrinology.

[13]  M. Rubin,et al.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  O. Tørring,et al.  Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  G. Divine,et al.  Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  M. Hochberg,et al.  Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  P. Houillier,et al.  Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  F. Melsen,et al.  Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. , 1999, Bone.

[19]  E. Siris,et al.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. , 1999, The New England journal of medicine.

[20]  F. Melsen,et al.  Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. , 1999, Bone.

[21]  S. Silverberg,et al.  To Treat or Not To Treat: Conclusions from the NIH Consensus Conferencea , 1999 .

[22]  Judith E. Adams,et al.  Bone Loss in Celiac Disease Is Related to Secondary Hyperparathyroidism , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  E. Thurfjell,et al.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.

[24]  J. Nordenström,et al.  Seventeen year follow-up study of bone mass in patients with mild asymptomatic hyperparathyroidism some of whom were operated on. , 1995, The European journal of surgery = Acta chirurgica.

[25]  E. Siris,et al.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  J. Monchik,et al.  Role of the oral calcium-loading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. , 1992, Surgery.

[27]  T. Clemens,et al.  Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  B. Hollis,et al.  Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. , 1989, The Journal of clinical endocrinology and metabolism.

[29]  C. Pak,et al.  Sequential Changes in Bone Density Before and After Parathyroidectomy in Primary Hyperparathyroidism , 1982, Investigative radiology.

[30]  H. Rasmussen,et al.  PRIMARY HYPERPARATHYROIDISM WITH INTERMITTENT HYPERCALCAEMIA: SERIAL OBSERVATIONS AND SIMPLE DIAGNOSIS BY MEANS OF AN ORAL CALCIUM TOLERANCE TEST , 1980, Clinical Endocrinology.

[31]  B. Clarke,et al.  Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial , 2008 .

[32]  Ph.D. Erik Nordenström M.D.,et al.  Recovery of Bone Mineral Density in 126 Patients after Surgery for Primary Hyperparathyroidism , 2004, World Journal of Surgery.

[33]  S. Silverberg,et al.  Therapeutic controversies in primary hyperparathyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[34]  J. Firpo,et al.  Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. , 1973, The Journal of clinical investigation.